Peptide policy: read the documents before the promise

Preparations and routes

Ten cumulative conditions[1]

1. Appendix A inclusion.
2. Appendix B identity and route.
3. Section 510-registered facility; valid certificate of analysis (COA) with Appendix B testing.
4. Original manufacturer: FDA registration, CGMP/FD&C compliance, physical location on COA; FDA-registered intermediaries perform/document manufacturer/COA validation.
5. Report products, serious events regardless causality, and quality issues to FDA and both compounding/destination states; patient labeling explains reporting. Products: ingredient/strength per unit, manufacturer/facility identifier, dosage form/route.
6. Label: compounded product; not for resale.
7. One listed active ingredient.
8. If oral, document adequate human oral bioavailability for the specific formulation.
9. Co-packaged or drug-containing devices: only FDA 510(k)-cleared syringes.
10. Other FD&C requirements, including sanitation and a valid patient-specific prescription.

Read the document status

The published notice concerns section 503A and does not extend this pathway to 503B. It describes discretion for state-licensed pharmacies, federal facilities and licensed physicians, and says HHS may revisit the policy if safety or quality concerns arise. The October 30 publication date should not be presented as a separately verified effective date.[2]

When saving an article about this development, save the linked policy and its date as well. In your notes, distinguish what the document actually says from what a commentator expects next. If a later headline sounds broader, compare the underlying documents before carrying that broader wording into a treatment discussion. A useful update identifies the changed passage, rather than merely adding a newer date to an older conclusion.

Identify the responsible business

FDA's Q&A says drugs compounded under section 503A conditions are exempt from CGMP requirements; outsourcing-facility drugs are subject to those requirements. Compounded products are not FDA-approved, and approval of a generic drug is a different regulatory status.[4]

Keep the original manufacturer named in the checklist separate from the compounder discussed in that FDA explanation. Ask the care team to write down which business performs which step. Then record who supplied each answer and whether you received a document or only a general assurance. This is a way to organize questions, not a method for a reader to certify a facility or product. We have not inspected a manufacturer, pharmacy, batch or COA for this guide.

Read the company's verbs

Hims & Hers' October 29 announcement previews Peptides+; BPC-157 and TB-500 are planned only when allowable. It does not establish current dispensing or treatment benefit.[3]

The company describes a forthcoming launch and a signup list. Its planned menu includes sermorelin, glutathione, B12, NAD+ and L-carnitine, while its cautionary statement identifies uncertainty about timing, availability, clinical data and future policy. These are company plans, not independently verified patient outcomes.[3]

For a provider comparison, create two columns: information you have confirmed for the service being offered to you, and information you still need. Put a future promise in the second column until you have an answer applicable to your situation. If you contact a provider, ask it to distinguish the announcement from the service available at the time of your inquiry. Keep that response with the offer, terms and date you are comparing.

Keep the clinical question open

FDA's current safety page lists BPC-157 among withdrawn nominations and retains concerns about immune responses, impurities and limited safety information. Withdrawal is not a finding of safety.[5]

The same FDA page retains safety concerns for other named peptides, including TB-500, and describes gaps in information about harm. Its entries should be read by substance and route, rather than treated as a common safety verdict for everything marketed as a peptide.[5]

For a scientific claim, write down the outcome you care about before reading the conclusion. Ask which observation in the cited study addresses that outcome, which people were studied, and what comparison was made. Mark any gap between that question and the claim being advertised. Bring the marked passage to a clinician rather than converting an incomplete match into a personal prediction. This guide does not assign a probability of benefit or recommend a regimen.

Use this update with the older reviews

Our linked provider reviews and compounding guides retain their earlier source dates. The BPC-157 profile also keeps its dated evidence record. Use this article for the policy context checked on October 30, and open the linked pages for their separately dated material. An added notice does not mean we rechecked every older price, service statement or clinical paper. If one of those details matters to your decision, identify it explicitly as a question that still needs a current answer.

Questions and answers